Sturgill M G, Nagabandi S R, Drachtman R A, Ettinger A G, Rubin J, Ettinger L J
Division of Pediatric Hematology-Oncology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, USA.
J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):523-5. doi: 10.1097/00043426-199711000-00006.
Immune thrombocytopenic purpura (ITP) is a common childhood illness characterized by thrombocytopenia secondary to shortened platelet survival. Medical therapy includes corticosteroids, intravenous immune globulin (IVIG), and IV Rho (D) immunoglobulin (anti-D). Individuals with Rh-negative blood generally do not respond to treatment with anti-D, but little information is currently available regarding the potential relationship between blood type and response to IVIG. This study was designed to characterize the relationship between ABO and Rh blood type and the response to IVIG in children and adolescents with newly diagnosed ITP.
A retrospective chart review was performed for 52 children and adolescents with newly diagnosed ITP initially treated with IVIG by the Division of Pediatric Hematology-Oncology at Robert Wood Johnson University Hospital in New Brunswick, New Jersey.
There were no significant differences in response rate or clinical outcome by ABO blood group or Rh type in children with ITP who received IVIG monotherapy as their initial treatment.
ABO blood group and Rh type do not appear to be prognostic factors when IVIG monotherapy is the initial treatment for childhood ITP.
免疫性血小板减少性紫癜（ITP）是一种常见的儿童疾病，其特征为血小板生存时间缩短继发血小板减少。医学治疗包括使用皮质类固醇、静脉注射免疫球蛋白（IVIG）以及静脉注射Rho（D）免疫球蛋白（抗-D）。Rh阴性血型的个体通常对抗-D治疗无反应，但目前关于血型与IVIG反应之间的潜在关系的信息较少。本研究旨在描述新诊断ITP的儿童和青少年中ABO和Rh血型与IVIG反应之间的关系。
对新泽西州新不伦瑞克市罗伯特·伍德·约翰逊大学医院儿科血液肿瘤学部最初接受IVIG治疗的52例新诊断ITP的儿童和青少年进行回顾性病历审查。
接受IVIG单一疗法作为初始治疗的ITP儿童，其ABO血型或Rh类型在反应率或临床结果方面无显著差异。
当IVIG单一疗法作为儿童ITP的初始治疗时，ABO血型和Rh类型似乎不是预后因素。
